Potential therapeutic effects of interleukin-35 on the differentiation of naïve T cells into Helios(+)Foxp3(+) Tregs in clinical and experimental acute respiratory distress syndrome

Wang, Chuanjiang; Xie, Ke; Li, Kefeng; Lin, Shihui; Xu, Fang

Regulatory T lymphocytes are important targets for the treatment of acute respiratory distress syndrome (ARDS). IL-35 is a newly identified IL-12 cytokine family member that plays an important protective role in a variety of immune system diseases by regulating Treg cell differentiation; however, the role of IL-35 in the pathogenesis of ARDS is still unclear. Here, we found that IL-35 was significantly elevated in adult patients with ARDS compared to controls. Additionally, IL-35 was positively and significantly correlated with IL-6, IL-10 and the oxygenation index (PaO2/FiO2 ratio) but negatively correlated with TNF-α, IL-1β and APACHE II score during ARDS. Moreover, the proportion of Treg/CD4(+) cells in the peripheral blood of ARDS patients and the expression of NF-κB in PMBCs were significantly higher than in healthy individuals. Recombinant IL-35 improved survival in a murine model of CLP-induced ARDS. Additionally, IL-35 administration decreased the inflammatory response, as reflected by lower levels of cytokines (including IL-2, TNF-α, IL-1β and IL-6) and less lung damage in CLP-induced ARDS. Furthermore, recombinant IL-35 reduced the apoptosis of lung tissue and the expression of NF-κB signalling in a CLP-induced ARDS model and increased the proportion of Treg cells in spleen and peripheral blood. In vitro experiments revealed that IL-35 can affect the phosphorylation of STAT5 during differentiation of naïve CD4(+) T lymphocytes into Foxp3(+)Helios(+) Tregs. Our findings suggest that IL-35 attenuates ARDS by promoting the differentiation of naïve CD4(+) T cells into Foxp3(+)Helios(+) Tregs, thereby providing a novel tool for anti-ARDS therapy.